Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học:" Summary of the primer on tumor immunology and the biological therapy of cancer"
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Summary of the primer on tumor immunology and the biological therapy of cancer | Journal of Translational Medicine BioMed Central Editorial Open Access Summary of the primer on tumor immunology and the biological therapy of cancer Yufeng Li1 Shujuan Liu1 Kim Margolin2 and Patrick Hwu 1 Address Department of Melanoma Medical Oncology the University of Texas M. D. Anderson Cancer Center Houston TX USA and 2Department of Medicine Division of Oncology University of Washington Seattle WA USA Email Yufeng Li - yufenli@mdanderson.org Shujuan Liu - SJLiu@mdanderson.org Kim Margolin - kmargoli@seattlecca.org Patrick Hwu - phwu@mdanderson.org Corresponding author Published 28 January 2009 Received 27 December 2008 _ -T_-mno - .11 I lozil A-ra cmi 1 I I Accepted 28 January 2009 Journal of Translational Medicine 2009 7 11 doi 10.1186 1479-5876-7-1 1 This article is available from http www.translational-medicine.com content 7 1 11 2009 Li et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.Org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The International Society for Biological Therapy of Cancer iSBTc is one of the premier destinations for interaction and innovation in the cancer biologics community . It provides a primer course each year during the annual meeting to address the most important areas of tumor immunology and immunotherapy. The course has been given by prominent investigators in the area of interest covering the core principles of cancer immunology and immunotherapy. The target audience for this program includes investigators from academic regulatory and biopharmaceutical venues. The program goal is to enable the attendees to learn the current status and the most recent advances in biologic therapies and to leverage this knowledge towards the improvement of cancer therapy. The 2008 immunologic primer course was held on October 30 at